<DOC>
	<DOCNO>NCT02837926</DOCNO>
	<brief_summary>The study aim identify global local determinant HPV vaccine acceptability , HPV vaccine uptake compliance well identify logistics programmatic issue country offer HPV vaccine , potential cervical cancer prevention strategy , mid-aged woman attend screening .</brief_summary>
	<brief_title>Comparing Health Services Interventions Prevention HPV-related Cancer</brief_title>
	<detailed_description>3000 woman age within age range 25-45 year old recruit ; 250-300 woman per country . These woman identify mean screen registry list screen clinical visit . Eligible woman receive study questionnaire HPV vaccine . Additionally , independently participate study questionnaire , accept get 3 HPV vaccine dos . Depending country preference , either Cervarix® ( Glaxosmithkline Biologicals , S.A. ) month 0 , 1 6 Gardasil® ( Sanofi Pasteur MSD SNC ) month 0 , 2 6 , administer . Safety data HPV vaccine compliance assess . A sub study Spain also analyze acceptability HPV vaccination sample woman age 35-40 yr identify poor screen attender . Two independent informed consent form provide ; one study questionnaire participation another HPV vaccine administration .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>woman within age range 2545 attend cervical cancer screen previous history HPV vaccine administration</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>